Development of anticancer agent targeting mucolipin

2022 Fiscal Year Final Research Report

• Project/Area Number: 20K09337
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 56010:Neurosurgery-related
• Research Institution: Kansai Medical University
• Principal Investigator: HAYASHI Mikio 関西医科大学, 医学部, 講師 (10368251)
• Co-Investigator(Kenkyū-buntansha): 岩田 亮一 関西医科大学, 医学部, 非常勤講師 (60580446)
• Project Period (FY): 2020-04-01 – 2023-03-31
• Keywords: 膠芽腫 / がん幹細胞 / イオンチャネル / 創薬

Outline of Final Research Achievements

Glioblastoma has a survival period of 15 months, and the development of new chemotherapeutic agents is desired. The existence of cancer stem cells has been proposed as a source of cancer development and treatment resistance. We have created novel compounds that attenuate the proliferation of cancer stem cells. Furthermore, a novel compound prolongs overall survival in glioblastoma model mice. These results suggest that the novel compounds may be applied as a new drug for glioblastoma.

Free Research Field

トランスレーショナルリサーチ

Academic Significance and Societal Importance of the Research Achievements

がん幹細胞は自己増殖しながら、分化したがん細胞を生み出す。そのため、がん幹細胞に作用する薬物が開発できれば、根治療法につながる。本研究は、がん幹細胞に有効な化合物を創り出した。この新規化合物はがん治療に広く波及する。